» Articles » PMID: 17363506

Blockade of the Phosphatidylinositol-3-kinase-Akt Signaling Pathway Enhances the Induction of Apoptosis by Microtubule-destabilizing Agents in Tumor Cells in Which the Pathway is Constitutively Activated

Overview
Journal Mol Cancer Ther
Date 2007 Mar 17
PMID 17363506
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Constitutive activation of the phosphatidylinositol-3-kinase (PI3K)-Akt signaling pathway is associated with the neoplastic phenotype in many human tumor cell types. Given the antiapoptotic role of this pathway, we examined whether its specific blockade might sensitize human tumor cells to the induction of apoptosis by various anticancer drugs. Although specific blockade of the PI3K-Akt pathway alone with inhibitors such as LY294002 did not induce cell death, it resulted in marked and selective enhancement of the induction of apoptosis by microtubule-destabilizing agents such as vincristine. This effect was apparent only in tumor cells in which the PI3K-Akt pathway is constitutively activated. Blockade of the PI3K-Akt pathway induced the activation of glycogen synthase kinase-3beta, which phosphorylates microtubule-associated proteins such as tau and thereby reduces their ability to bind and stabilize microtubules. The consequent destabilization of microtubules induced by the inhibition of PI3K-Akt signaling appeared to increase their sensitivity to low concentrations of microtubule-destabilizing agents that alone do not lead to the disruption of cytoplasmic microtubules in tumor cells. Such a synergistic effect on microtubule integrity was not apparent for stable microtubules in the neurites of neuronal cells. These results suggest that the administration of a combination of a PI3K-Akt pathway inhibitor and a microtubule-destabilizing agent is a potential chemotherapeutic strategy for the treatment of tumor cells in which this signaling pathway is constitutively activated.

Citing Articles

First total synthesis, antitumor evaluation and target identification of mornaphthoate E: A new tubulin inhibitor template acting on PI3K/Akt signaling pathway.

Shan P, Ye T, Tang Y, Song H, Wang C, Zhu K Acta Pharm Sin B. 2024; 14(5):2177-2193.

PMID: 38799630 PMC: 11120283. DOI: 10.1016/j.apsb.2024.02.012.


Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.

Lu Z, Lai Q, Li Z, Zhong M, Jiang Y, Feng L Curr Med Sci. 2024; 44(2):298-308.

PMID: 38619682 DOI: 10.1007/s11596-024-2847-5.


mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.

Hu Y, Chen F, Sun S, Xv L, Wang X, Wang M Front Oncol. 2024; 14:1312634.

PMID: 38344201 PMC: 10854197. DOI: 10.3389/fonc.2024.1312634.


Effect of the Rho-Kinase/ROCK Signaling Pathway on Cytoskeleton Components.

Guan G, Cannon R, Coates D, Mei L Genes (Basel). 2023; 14(2).

PMID: 36833199 PMC: 9957420. DOI: 10.3390/genes14020272.


PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression.

Deng S, Leong H, Datta A, Gopal V, Kumar A, Yap C Cancers (Basel). 2022; 14(7).

PMID: 35406424 PMC: 8997157. DOI: 10.3390/cancers14071652.